Tricida, Inc.
TCDA
$0.00
Change (1 day)
$13.85
Year High
$0.04
Year Low
Categories
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
P/E ratio for Tricida, Inc. (TCDA)
P/E ratio as of 2021: -2.46
According to Tricida, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.46. At the end of 2020 the company had a P/E ratio of -1.33.
P/E ratio history for Tricida, Inc. from 2016 to 2021
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2021 | -2.46 |
| 2020 | -1.33 |
| 2019 | -10.14 |
| 2018 | -5.08 |
| 2017 | -3.45 |
| 2016 | -6.49 |